HTA54 Cost-Effectiveness Analysis of Olaparib and Niraparib With Abiraterone Versus Abiraterone for First-Line Treatment of BRCA Mutated Metastatic Castration-Resistant Prostate Cancer in Taiwan
Abstract
Authors
LIN PEI-LIEN Ming-Neng Shiu Shih-Tsung Huang